CRSP
Price
$32.65
Change
-$1.54 (-4.50%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
2.93B
39 days until earnings call
MRNA
Price
$25.70
Change
-$2.02 (-7.29%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
10.72B
28 days until earnings call
Ad is loading...

CRSP vs MRNA

Header iconCRSP vs MRNA Comparison
Open Charts CRSP vs MRNABanner chart's image
CRISPR Therapeutics AG
Price$32.65
Change-$1.54 (-4.50%)
Volume$51.2K
Capitalization2.93B
Moderna
Price$25.70
Change-$2.02 (-7.29%)
Volume$218.33K
Capitalization10.72B
CRSP vs MRNA Comparison Chart
Loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRSP vs. MRNA commentary
Apr 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a Hold and MRNA is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 03, 2025
Stock price -- (CRSP: $34.19 vs. MRNA: $27.72)
Brand notoriety: CRSP: Not notable vs. MRNA: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 79% vs. MRNA: 104%
Market capitalization -- CRSP: $2.93B vs. MRNA: $10.72B
CRSP [@Biotechnology] is valued at $2.93B. MRNA’s [@Biotechnology] market capitalization is $10.72B. The market cap for tickers in the [@Biotechnology] industry ranges from $308.32B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whileMRNA’s FA Score has 1 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • MRNA’s FA Score: 1 green, 4 red.
According to our system of comparison, MRNA is a better buy in the long-term than CRSP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 4 TA indicator(s) are bullish while MRNA’s TA Score has 5 bullish TA indicator(s).

  • CRSP’s TA Score: 4 bullish, 6 bearish.
  • MRNA’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, MRNA is a better buy in the short-term than CRSP.

Price Growth

CRSP (@Biotechnology) experienced а -12.74% price change this week, while MRNA (@Biotechnology) price change was -11.94% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.57%. For the same industry, the average monthly price growth was -10.69%, and the average quarterly price growth was -14.76%.

Reported Earning Dates

CRSP is expected to report earnings on May 12, 2025.

MRNA is expected to report earnings on May 01, 2025.

Industries' Descriptions

@Biotechnology (-8.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MRNA($10.7B) has a higher market cap than CRSP($2.93B). CRSP YTD gains are higher at: -13.135 vs. MRNA (-33.333). CRSP has higher annual earnings (EBITDA): -447.31M vs. MRNA (-3.39B). MRNA has more cash in the bank: 7.03B vs. CRSP (1.9B). CRSP has less debt than MRNA: CRSP (224M) vs MRNA (747M). MRNA has higher revenues than CRSP: MRNA (3.2B) vs CRSP (35M).
CRSPMRNACRSP / MRNA
Capitalization2.93B10.7B27%
EBITDA-447.31M-3.39B13%
Gain YTD-13.135-33.33339%
P/E RatioN/AN/A-
Revenue35M3.2B1%
Total Cash1.9B7.03B27%
Total Debt224M747M30%
FUNDAMENTALS RATINGS
CRSP vs MRNA: Fundamental Ratings
CRSP
MRNA
OUTLOOK RATING
1..100
5876
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
65
Fair valued
PROFIT vs RISK RATING
1..100
10098
SMR RATING
1..100
9496
PRICE GROWTH RATING
1..100
8865
P/E GROWTH RATING
1..100
762
SEASONALITY SCORE
1..100
4813

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MRNA's Valuation (65) in the Biotechnology industry is in the same range as CRSP (67). This means that MRNA’s stock grew similarly to CRSP’s over the last 12 months.

MRNA's Profit vs Risk Rating (98) in the Biotechnology industry is in the same range as CRSP (100). This means that MRNA’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's SMR Rating (94) in the Biotechnology industry is in the same range as MRNA (96). This means that CRSP’s stock grew similarly to MRNA’s over the last 12 months.

MRNA's Price Growth Rating (65) in the Biotechnology industry is in the same range as CRSP (88). This means that MRNA’s stock grew similarly to CRSP’s over the last 12 months.

MRNA's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for CRSP (76). This means that MRNA’s stock grew significantly faster than CRSP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRSPMRNA
RSI
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
Bearish Trend 4 days ago
83%
Bearish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 11 days ago
81%
Bullish Trend 11 days ago
78%
Declines
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
78%
Aroon
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
78%
View a ticker or compare two or three
Ad is loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MAIFX9.160.04
+0.44%
MoA International Fund
HDQVX16.260.01
+0.06%
Janus Henderson Responsible Intl DivS
RYFAX83.56N/A
N/A
Rydex Financial Services H
BCSCX8.55N/A
N/A
BlackRock Commodity Strategies Inv C
MEMRX30.33-0.03
-0.10%
MFS Emerging Markets Equity R1